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Growth hormone (GH) deficiency is caused by congenital or acquired causes and occurs in childhood or adulthood. GH replacement 
therapy brings benefits to body composition, exercise capacity, skeletal health, cardiovascular outcomes, and quality of life. Before 
initiating GH replacement, GH deficiency should be confirmed through proper stimulation tests, and in cases with proven genetic 
causes or structural lesions, repeated GH stimulation testing is not necessary. The dosing regimen of GH replacement therapy should 
be individualized, with the goal of minimizing side effects and maximizing clinical improvements. The Korean Endocrine Society 
and the Korean Society of Pediatric Endocrinology have developed a position statement on the diagnosis and treatment of GH defi-
ciency. This position statement is based on a systematic review of evidence and expert opinions. 
Keywords: Growth hormone; Dwarfism, pituitary; Hypopituitarism; Hormone replacement therapy 
1. Diagnosis of growth hormone deficiency in adults 
1.  The insulin tolerance test is recommended as the stan-
dard test for diagnosing growth hormone (GH) deficien-
cy (B).
2.  When GH deficiency is suspected, but an insulin toler-
ance test is contraindicated, two or more GH stimulation 
tests (GH-releasing hormone—arginine, glucagon, le-
vodopa, or clonidine stimulation tests) should be admin-
istered (B).
3.  GH deficiency cannot be ruled out even if insulin-like 
growth factor-1 (IGF-1) levels are normal. However, low 
serum IGF-1 levels may be indicative of GH deficiency 
in individuals who do not have a history of poorly con-
trolled diabetes, chronic liver disease, or treatment with 
oral contraceptives (C).
4.  GH deficiency can be diagnosed without GH stimulation 
testing when the typical clinical characteristics of GH 
deficiency are present, accompanied by deficiencies in 
three or more pituitary hormones with low serum IGF-1 
levels (B).
5.  Repeated GH stimulation testing should be performed in 
patients with childhood-onset GH deficiency if they do 
not have a proven genetic cause of GH deficiency or ir-
reversible damage (B).
6.  Adult patients with irreversible pituitary damage should 
not receive repeated GH stimulation tests (B). 
2. Treatment of growth hormone deficiency in adults 
1.  Unless contraindicated, GH therapy is recommended for 
patients with GH deficiency. GH therapy should start 
from a low dose, considering the patient’s age, sex, and 
estrogen levels (A).
2.  Clinical improvements, side effects, and targeting serum 
IGF-1 levels within the age-adjusted reference range 
should be considered when adjusting the GH dose (A). 
3.  During the adjustment period, IGF-1 levels should be 
monitored monthly or bimonthly. Once the maintenance 
level is determined, IGF-1 levels should be monitored 
around twice per year. Monitoring should include an 
evaluation of the patient’s clinical response, side effects, 
and IGF-1 levels (B).
3.  Diagnosis and treatment of growth hormone deficien-
cy in children and adolescents
1.  Two or more GH stimulation tests should be adminis-
tered when GH deficiency is suspected in children (A).
2.  Repeated GH stimulation tests are not required in GH 
patients with pituitary lesions or a proven genetic cause 
of GH deficiency (C).
3.  GH replacement should be continued in children and ad-
olescents until the epiphyseal plates close or their full 
height is reached (C).
4.  GH replacement should be resumed as soon as possible 
in patients with GH deficiency during transition (B).
4. Benefits of growth hormone treatment 
1.  GH treatment improves body composition, exercise ca-
pacity, and bone mineral density in patients with GH de-
ficiency (A). 
2.  GH treatment lowers the risk of cardiovascular disease 
in patients with GH deficiency, but there is insufficient 
evidence regarding its effects on mortality reduction (B).
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INTRODUCTION
Growth hormone (GH) deficiency can be categorized into 
childhood-onset and adult-onset. Childhood-onset GH deficien-
cy can be further categorized as congenital, acquired, or idio-
pathic. Adult-onset GH deficiency is generally acquired, al-
though GH deficiency in adults can also occur as a continuation 
of childhood-onset GH deficiency. The congenital causes are 
mutations of genes related to GH synthesis and GH receptors 
and developmental structural disabilities in the brain. The main 
causes of acquired GH deficiency are tumors in the pituitary 
gland and hypothalamus, the treatment of such tumors with sur-
gery or radiation, infiltrative diseases, vascular damage, and in-
fections (Table 1) [1,2]. 
The most common cause of adult-onset GH deficiency is hy-
pothalamic-pituitary tumors—either the tumor itself, or surgery 
3.  GH treatment improves quality of life in patients with 
GH deficiency (A).
5. Risks and side effects of growth hormone treatment
1.  GH treatment is contraindicated in patients with an ac-
tive malignancy (except basal cell or squamous cell skin 
cancers) (A).
2.  Changes in blood glucose levels should be observed dur-
ing the course of GH treatment in patients with diabetes 
mellitus, who may require their antidiabetic medication 
to be adjusted (B).
3.  Thyroid and adrenal gland function should be monitored 
during GH treatment in patients with hypopituitarism 
(B).
Table 1. Cause of Growth Hormone Deficiency 
Congenital Acquired
Genetic
  Transcription factor defects (PIT-1, PROP-1, LHX3/4, HESX-1, PITX-2)
  GHRH receptor gene defects
  GH secretagogue receptor gene defects
  GH gene defects
  GH receptor/post receptor defects
Neoplastic 
  Pituitary adenoma
  Craniopharyngioma
  Rathke’s cleft cyst
  Glioma/astrocytoma
  Germinoma
  MetastaticAssociated with brain structural defects
  Agenesis of corpus callosum
  Septo-optic dysplasia




  Arachnoid cyst
Infiltrative/granulomatous disease




  Head injury
  Pituitary tumor apoplexy 
  Sheehan’s syndrome
  Subarachnoid hemorrhage
Associated with midline facial defects
  Single central incisor
  Cleft lip/palate Treatment of pituitary and hypothalamic diseases
  Cranial irradiation
  Surgery of the pituitary or hypothalamus
Central nervous system infection
  Idiopathic
Modified from Molitch et al. [1]; and Melmed [2], with permission from Massachusetts Medical Society.
PIT-1, pituitary transcription factor-1; PROP-1, prophet of pit-1; LHX3/4, LIM class homeobox transcription factor Lhx3, 4; HESX-1, homeobox-1; 
PITX-2, paired-like homeodomain transcription factor-2; GHRH, growth hormone-releasing hormone; GH, growth hormone.
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or radiation treatment performed to treat the tumor. Although it 
is rare for pituitary microadenoma to present with hypopituita-
rism, pituitary macroadenoma presents with at least one pitu-
itary hormone deficiency in approximately 30% to 60% of cases 
[3]. The main mechanism of hormone deficiency is disruption 
of circulation due to pressure on the portal veins of the pituitary 
stalk [4]. Hypopituitarism can also occur after the removal of 
pituitary tumors, but surgery can lead to a 50% recovery of tu-
mor-induced hypopituitarism [5]. However, GH is the least re-
covering pituitary hormone [4]. Radiation also induces GH de-
ficiency. The risk of GH deficiency after intracranial radiation is 
higher in younger patients, and increases with the time after ra-
diation therapy [6]. If the amount of radiation is above 40 Gy, 
there is a 50% chance of GH deficiency [7].
GH deficiency occurs in 25% of patients with head injury or 
subarachnoid hemorrhage [8,9]. Some patients recover with 
time, while others deteriorate; therefore, pituitary hormone lev-
els in these patients should be monitored upon admission and at 
regular intervals thereafter. 
Clinically, patients with GH deficiency report increased body 
fat, decreased muscle mass, lethargy, and decreased quality of 
life [10]. However, the presenting symptoms such as fatigue and 
weakness are nonspecific and common. Therefore, controversy 
has persisted regarding the correct diagnosis and appropriate 
treatment of GH deficiency. The Insurance Committee of the 
Korean Endocrine Society therefore developed a guideline for 
the diagnosis and treatment of GH deficiency, as cases of GH 
deficiency increase and some issues arise regarding insurance 
reimbursements in South Korea. 
METHODS USED IN THE DEVELOPMENT 
OF THIS GUIDELINE 
This guideline was developed by the Insurance Committee of 
the Korean Endocrine Society in consultation with the Korean 
Neuroendocrine Study Group, and the Korean Society of Pedi-
atric Endocrinology. Since there are currently no diagnostic 
guidelines for GH deficiency and few domestic research has 
been conducted on this topic, the basis of this guideline was 
formed by consensus from panel discussion of experts, and the 
review of existing literature. When evidence was insufficient, 
recommendations were written according to experts’ opinions. 
When there were differences in opinions, a majority vote was 
taken. Each recommendation was graded according to the 
strength of evidence supporting the recommendation, as defined 
in Table 2. 
DISCUSSION OF THE RECOMMENDATIONS
1. Diagnosis of growth hormone deficiency in adults 
GH deficiency is suspected in patients with suggestive clinical 
presentations (increased body fat, decreased muscle mass, leth-
argy, and decreased quality of life), and it is diagnosed through 
GH stimulation tests. An evaluation for GH deficiency should 
be considered in patients with conditions that can cause GH de-
ficiency, since GH deficiency can be misdiagnosed in patients 
who only have non-specific clinical symptoms such as lethargy, 
weakness, and obesity. Before GH secretion is tested, other de-
ficient hormones should be supplemented. Since GH is released 
in spurts, GH deficiency is diagnosed through GH stimulation 




A When there is a clear rationale for the recommendations: 
When manifold randomized controlled trials that can be generalized because they have sufficient test or meta-analysis results  
support a recommendation.
B When there is a reliable basis for the recommendations: 
When reasonable grounds support this through well-performed cohort studies or patient—control group studies.
C When there is a possible basis for the recommendations: 
When relevant grounds are seen through randomized clinical studies or case reports and observational studies carried out in a 
small institution, despite their inherent unreliability.
E Expert recommendations: 
There is no basis to support the recommendations, but they are supported by expert opinion or expert clinical experience.
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tests such as the insulin tolerance test (ITT), the growth hor-
mone-releasing hormone (GHRH), arginine, glucagon, levodo-
pa, and clonidine stimulation tests. There is no single gold-stan-
dard test, but the ITT is a major GH stimulation test. The use of 
GHRH is withdrawn in South Korea as well as in the United 
States. The basic principle of GH stimulation test is consecu-
tively measuring blood GH levels after an administration of a 
medication that rapidly stimulates GH. The highest GH level in 
the samples is then interpreted as the patient’s GH response. Ta-
ble 3 summarizes the methods, standards, and precautions for 
GH stimulation tests. 
1.1. The insulin tolerance test is recommended as the 
standard test for diagnosing GH deficiency.
1.2. When GH deficiency is suspected, but an ITT is con-
traindicated, two or more GH stimulation tests (GHRH- 
arginine, glucagon, levodopa, or clonidine stimulation 
tests) should be administered.
The ITT is recommended as the standard test for the diagno-
sis of GH deficiency. ITT has been validated as a standard test 
for GH deficiency, but it causes hypoglycemia; therefore, it is 
contraindicated in elderly patients and patients with a history of 
epilepsy or cardiovascular disease due to its risks [11]. Even 
healthy individuals should be continuously monitored during 
ITT. In obese patients with insulin resistance, a greater dose of 
insulin is injected to induce hypoglycemia, and this process in-
creases the risk of delayed hypoglycemia. ITT is also difficult to 
replicate, since the response to ITT varies from occasion to oc-
casion in healthy individuals. The response to ITT also depends 
on the menstrual cycle. 
Aimaretti et al. [12] reported that injecting arginine, which 
suppresses the secretion of hypothalamic somatostatin, together 
with GHRH served as a potent and safe GH stimulation test. 
Biller et al. [13] compared five types of GH stimulation tests. In 
their study, five stimulation tests were administered in random 
order to 39 patients with panhypopituitarism, 21 patients with 
either isolated GH deficiency or no more than one additional pi-
tuitary hormone deficiency, and 34 healthy controls matched by 
age, sex, and body mass index (BMI). At a GH level of 5.1 μg/L, 
ITT had 96% sensitivity and 92% specificity, and the GHRH-
arginine test had a similar diagnostic validity at a GH level of 
Table 3. Dynamic Tests for Diagnosing GH deficiency
Hormone test Procedure GH cut-points, µg/L Consideration
ITT Administer insulin, 0.05–0.15 U/kg iv




Glucose should drop <40 mg/dL
Contraindication: a history of seizures, coronary artery 
disease, pregnancy, or age >65 yr
GHRH-arginine Administer GHRH, 1 µg/kg (max 100 µg) iv  
followed by an arginine infusion 0.5 g/kg  
(max 35 g) over 30 min
Sample blood at 0, 30, 45, 60, 75, 90, 105, and  
120 min for GH
>4 µg/L but cutoffs for 
GH response should 
be correlated to BMI
Can give false normal GH response if GHD is due to 
hypothalamic damage
Glucagon Administer glucagon, 1 mg (1.5 mg if weight  
>90 kg) im
Sample blood at 0, 30, 60, 90, 120, 150, 180, 210, 
and 240 min for GH and glucose
>3 µg/L (if BMI  
≥25 kg/m2, >1 µg/L)
Obesity may blunt GH response to stimulation
Contraindication: severe fasting hyperglycemia  
>180 mg/dL
Nausea, vomiting, headache, and delayed hypoglyce-
mia may occur
Levodopa Administer Levodopa 500 mg po
Sample blood at 0, 60, 90, and 120 min for GH
>3 µg/L Nausea, vomiting, dizziness, and headache may occur
Clonidine Administer clonidine, 0.15 mg/m2 (max 0.25 mg) po
Sample blood at 0, 30, 60, 90, and 120 min for GH
>3 µg/L Hypotension and drowsiness may occur
Contraindication: a history of coronary artery disease
Macimorelin Administer 0.5 mg/kg, oral solution >2.8 µg/L Avoid concomitant use with drugs known to prolong 
QT interval; hypothalamic disease may not be accu-
rately diagnosed side effect: mild dysgeusia 
GH, growth hormone; ITT, insulin-tolerance test; iv, intravenous; AACE, American Association of Clinical Endocrinologists; ES, Endocrine Society; 
GHRH, growth hormone-releasing hormone; BMI, body mass index; GHD, growth hormone deficiency; im, intramuscular; po, per os.
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4.1 μg/L, with 95% sensitivity and 91% specificity. GHRH, 
however, stimulates the pituitary gland directly and may result 
in false negatives in patients with disorders in the hypothalamus 
or a history of radiation treatment. The GH level for the GHRH-
arginine test needs to be adjusted in patients who are older or 
have a higher BMI [14,15]. A higher BMI also leads to a slight-
ly lower GH response in ITT, but it is not recommended to ad-
just the GH levels for the diagnostic cut-point [16]. For tests us-
ing arginine alone, a GH level of 0.4 μg/L was identified as a 
suitable cut-point; however, this low value compromises diag-
nostic accuracy, and this test is therefore not recommended. 
Glucagon indirectly stimulates GH by stimulating insulin se-
cretion; since the GH response is delayed, the glucagon stimula-
tion test requires a minimum of 3 hours to complete and poses a 
risk of delayed hypoglycemia. For this test, intramuscular or 
subcutaneous injection is more effective than intravenous injec-
tion. The GH level for diagnosis is adequate at 3 μg/L, while in 
patients with obesity (BMI >25 kg/m2) whose GH response is 
less sensitive, the GH level for diagnosis is 1 μg/L [17-21]. Al-
though higher blood glucose levels are associated with a weaker 
GH response, specific GH levels for diagnosis according to 
blood glucose levels have not been determined yet [22]. Side ef-
fects include nausea, vomiting, and headaches; furthermore, se-
vere hypotension, hypoglycemia, and convulsions have been re-
ported in the elderly. 
Levodopa stimulates GH through dopamine receptors in the 
hypothalamus, and clonidine through releasing GHRH via alpha 
receptors. Levodopa and clonidine are weak GH stimulators, so 
a diagnosis is possible when a sensitive method of GH measure-
ment is used. There are lack of data regarding the optimal GH 
cut-off values according to age, sex, BMI, blood glucose levels, 
or the presence of any underlying disorders. 
Macimorelin, an oral GH secretagogue receptor-1a agonist 
that was recently approved in the United States and Europe, 
stimulates GH release with similar sensitivity (92%) and speci-
ficity (96%) to ITT, and has fewer side effects [23]. A common 
side effect is a slight disturbance in taste that improves with 
time, although a severe side effect reported was long QT inter-
val on electrocardiography. Macimorelin is not yet introduced 
in South Korea. 
The analytical method of determining GH levels has a major 
impact on the GH cut-off value for the diagnosis of GH defi-
ciency. Thus, it is important to ensure that accurate measure-
ments of GH are applied. However, GH in blood samples is 
made up of diverse isoforms and isomers, of which the 22 and 
20 kDa forms are the most common. Furthermore, GH binding 
proteins can bind up to 50% of GH in the blood, which can in-
terfere with the immunoassay of GH. Moreover, institutions 
measure GH in different ways. This variation in GH measure-
ment underscores the importance of using the GH calibration 
standard 98 of 574 of the National Institute for Biological Stan-
dards and Control and using highly purified recombinant pitu-
itary GH [24]. All manufacturers of measurement equipment 
should specify the validity of the assays, the GH isoforms mea-
sured, the analytes, the antibodies used, and whether GH bind-
ing proteins interfere with the measurements. 
1.3. GH deficiency cannot be ruled out even if IGF-1 
levels are normal. However, low serum IGF-1 levels 
may be indicative of GH deficiency in individuals who 
do not have a history of poorly controlled diabetes, 
chronic liver disease, or treatment with oral contracep-
tives.
1.4. GH deficiency can be diagnosed without GH stimu-
lation testing when the typical clinical characteristics 
of GH deficiency are present, accompanied by deficien-
cies in three or more pituitary hormones with low se-
rum IGF-1 levels.
GH deficiency cannot be ruled out even when serum IGF-1 
levels are normal [13,25-27]. Higher BMIs are associated with 
a weaker GH response and increased IGF-1 levels [28]. Howev-
er, if a patient with a high BMI has a low IGF-1 level, it can be 
considered as GH deficiency.
GH stimulation tests can be omitted if there are abnormally 
low levels of three or more pituitary hormones and IGF-1 levels 
are low (at least 2.0 standard deviations lower than normal), if 
the patient has a structural hypothalamic-pituitary condition, if 
the patient has a genetic condition that impacts the hypothalam-
ic-pituitary axis, and if there is a structural lesion in the hypo-
thalamus or pituitary gland [1,25,29].
1.5. Repeated GH stimulation testing should be per-
formed in patients with childhood-onset GH deficiency 
if they do not have a proven genetic cause of GH defi-
ciency or irreversible damage. 
1.6. Adult patients with irreversible pituitary damage 
should not regularly receive repeated GH stimulation 
tests.
When patients with idiopathic child-onset GH deficiency are 
re-evaluated in adulthood, most show normal GH secretion [30]. 
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However, GH deficiency due to structural conditions, including 
tumors, surgery, radiation, and genetic disorders, do not im-
prove in adulthood, so GH stimulation tests is not needed to be 
repeated in such patients [31] .
2. Treatment of growth hormone deficiency in adults 
2.1. Unless contraindicated, GH therapy is recommended 
for patients with GH deficiency. GH therapy should 
start from a low dose, considering the patient’s age, sex, 
and estrogen levels.
2.2. Clinical improvements, side effects, and targeting se-
rum IGF-1 levels within the age-adjusted reference 
range should be considered when adjusting the GH dose.
Unless contraindicated, GH replacement therapy is recom-
mended for patients with GH deficiency diagnosed through GH 
stimulation tests. Patients should be started on low doses, since 
side effects are dose-dependent [32]. Common side effects in-
clude fluid retention, arthralgia, muscle pain, sensory distur-
bances, carpal tunnel syndrome, sleep apnea, sleep disorders, 
and dyspnea. Most of these side effects occur in around 20% of 
patients, in a dose-dependent manner. Side effects are more fre-
quent in elderly, obese, and female patients, but subside after 
the dose is lowered [33]. The GH doses for adults were initially 
extrapolated based on body weight from dose recommendations 
for children. However, shifting from weight-based to individu-
alized dose recommendations reduces side effects by half [34].
GH secretion decreases with age, and the side effects of GH 
are more common in elderly patients. Therefore, the appropriate 
therapeutic levels of GH are lower in elderly individuals and 
higher in younger individuals [35]. For individuals between the 
ages of 30 to 60, a suitable starting dose is 0.2 to 0.3 mg/day 
(0.8 to 1.2 IU/day). For those below the age of 30, a higher dose 
of 0.4 to 0.5 mg/day (1.6 to 2.0 IU/day) is possible, while in in-
dividuals above the age of 60, the starting dose should be 0.1 to 
0.2 mg/day (0.4 to 0.8 IU/day) and increased slowly thereafter 
(Fig. 1). The dosage should be increased by 0.1 to 0.2 mg/day 
(0.4 to 0.8 IU/day) monthly or bimonthly, and the maintenance 
level should be determined based on an evaluation of the pa-
tient’s clinical response, side effects, and the normal range of 
IGF-1 levels for the patient’s age group [1]. Although a normal 
IGF-1 level is targeted, the evidence remains unclear. Clinical 
responses can usually be observed after 6 months of treatment. 
Females generally show higher GH resistance, and therefore 
require higher starting and maintenance doses [36]. Estrogen 
stimulates suppressor of cytokine signaling 2 (SOCS2), a spe-
cific non-competitive suppressor of GH in the liver [37], where 
85% of serum IGF-1 originates. Since oral estrogen suppresses 
IGF-1, a higher dose of GH is required to maintain the same 
IGF-1 levels in females [37]. Even at the same IGF-1 levels, 
GH has less effect on body fat, low-density lipoprotein choles-
terol, and bone turnover markers in females [38]. When oral es-
trogen is changed to transdermal estrogen, GH requirement is 
reduced [39].
2.3. During the adjustment period, IGF-1 levels should 
be monitored monthly or bimonthly. Once the mainte-
nance level is determined, IGF-1 levels should be moni-
tored around twice per year. monitoring should include 
an evaluation of the patient’s clinical response, side ef-
fects, and IGF-1 levels.
During the adjustment period, Adequacy of GH dose includ-
ing an evaluation of the patient’s clinical response, side effects, 
and IGF-I levels [1] should be monitored monthly or bimonthly. 
Once the maintenance level is determined, IGF-1 levels should 
be monitored every six months (Fig. 1). The blood levels of lip-
id and fasting glucose should be tested every year, and if the ini-
tial bone mineral density is abnormal, bone mineral density 
should be re-evaluated every 1.5 to 2 years. Additionally, waist 
circumference and quality of life should be evaluated. If the pa-
tient is already taking thyroid or adrenal hormones, their doses 
should be adjusted after GH is introduced. These recommenda-
tions are based on empirical experience. Although it is unclear 
precisely how long GH should be administered, if there is no 
clear response to GH replacement after at least 1 year, treatment 
can be suspended [1].
The recently developed long-acting GH is formulated to be 
taken once a week or once a month instead of daily. Long-acting 
GH may be more effective because it reduces the inconvenience 
and discomfort of daily GH injections, thereby increasing com-
pliance. A recently published meta-analysis reported long-acting 
GH and daily GH to have similar efficacy and safety profiles 
[40]. However, IGF-1 levels were significantly elevated in chil-
dren with GH deficiency who received long-acting GH. Thus, 
additional research on long-acting GH should investigate how 
the peak and trough levels of GH and IGF-1 influence efficacy 
and safety, how the dose should be adjusted, when IGF-1 levels 
should be monitored, and how to compare long-term cost-effec-
tiveness between daily and long-acting GH preparations [41]. 
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3.  Diagnosis and treatment of growth hormone deficiency 
in children and adolescents
3.1. Two or more GH stimulation tests should be admin-
istered when GH deficiency is suspected in children.
Childhood onset GH deficiency may be a long lasting endo-
crine conditions, starting in childhood and continuing into adult-
hood. Diagnostic workup of childhood onset GH deficiency in-
clude auxology, bone age view, measurement of IGF-1 and IGF 
binding protein 3, GH stimulation tests, brain imaging and, ge-
netic tests if needed [42]. GH stimulation test is one of the most 
important diagnostic tools, but it is also intrusive and is accom-
panied by a risk of side effects [43]. The validity and reproduc-
ibility of GH stimulation tests have also been called into ques-
tion [44,45]. Therefore, to diagnose GH deficiency, two or more 
GH stimulation tests should be administered. Children diag-
nosed with GH deficiency should receive GH replacement six 
to seven times a week, at 22 to 35 μg/kg/day (0.16 to 0.24 mg/
kg/week) or 12 IU (4 mg) per body surface area (m2)/week by 
subcutaneous injection until their epiphyseal plates close [46].
3.2. Repeated GH stimulation tests are not required in 
GH patients with pituitary lesions or a proven genetic 
cause of GH deficiency.
Controversy exists regarding the management in the transi-
tion period of adolescence of children or adolescents with GH 
deficiency. If a patient requires ongoing GH therapy, GH stimu-
lation tests should be re-administered to reevaluate the function 
of the hypothalamic-pituitary axis. However, in patients with a 
high probability of irreversible GH deficiency, re-evaluation of 
GH status is not necessary [25]. Patients with structural lesions 
in the hypothalamus or pituitary gland or other structural prob-
lems, such as tumors, have a high risk of persistent GH defi-
ciency [47,48]. Several genetic defects may also lead to an irre-
versible GH deficiency [49]. Therefore, GH stimulation tests is 
not need to be repeated in patients with definite genetic or struc-
Adults with confirmed GH deficiency
GH starting dose: 
≤60 yr: 0.2–0.3 mg/day












Continue with the same GH dose
Check IGF-I levels every 6 mo
Fig. 1. Algorithm for growth hormone (GH) therapy in GH deficiency adults. IGF-1, insulin-like growth factor-1.
Yes
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tural pituitary abnormalities.
3.3. GH replacement should be continued in children 
and adolescents until the epiphyseal plates close or 
their full height is reached.
The benefits of GH replacement during the transition period 
of adolescence are widely recognized. Childhood-onset GH de-
ficiency contributes to low bone mass and an increased risk of 
fracture in adulthood [50]. It also results in developmental bone 
mass deficits both at the time of diagnosis and final height [51]. 
In a previous study, when GH replacement was resumed, body 
composition improved, with a 14% increase in muscle mass and 
a 7% decrease in body fat over a 2-year period [35]. Some stud-
ies have reported deterioration in dyslipidemia after suspension 
of GH replacement in patients with childhood-onset GH defi-
ciency [52]. Other studies have reported a reduction in cardiac 
dimensions after suspension of GH therapy during this transi-
tion period [53]. Therefore, GH replacement should be main-
tained until either the epiphyseal plates close or the final height 
is reached, since there are various benefits besides height gain.
3.4. GH replacement should be resumed as soon as possi-
ble in patients with GH deficiency during adolescence.
It is widely known that appropriate GH replacement during 
the transition period of adolescence is necessary [54]. The pur-
pose of GH replacement during this transition period is to main-
tain the continuity of hormonal care and to prevent health prob-
lems. Several studies have reported a risk of dropout among pa-
tients with GH deficiency who did not receive GH replacement 
during this transition period [54]. In one study, 21% of patients 
in puberty discontinued GH treatment without a comprehensive 
evaluation, and among those patients, 18% were lost to follow-
up [55]. Thus, strategies for successful transition including stan-
dardized referral systems should be established [56]. If GH re-
placement is discontinued in such patients, it should be resumed 
as soon as possible. 
4. Benefits of growth hormone treatment
4.1. GH treatment improves body composition, exercise 
capacity, and bone mineral density in patients with GH 
deficiency.
GH deficiency can cause decreased bone mineral density, 
muscle strength, and exercise capacity, deterioration in memory, 
decreased physical activity and vitality, lethargy, difficulty in 
concentration, and sleep disorders [57,58]. Patients also are ex-
posed to a high risk of cardiovascular disease due to central 
obesity, dyslipidemia, or insulin resistance [59-61]. 
Several studies consistently reported that GH treatment had 
the significant effect on body composition including decrease in 
fat mass and increase in muscle mass [62,63]. It was further re-
ported that GH replacement led to a decrease preferentially in 
visceral fat [64] and an increase in lean body mass [27,65], and 
improvements in muscle function [65] and lipid metabolism 
[66] can be expected as well. Studies in South Korea confirmed 
the tendency for GH treatment to achieve reductions in weight, 
body fat, and insulin resistance [67-70]. 
Published data have shown that bone mineral density in adults 
with GH deficiency is lower than the age- and sex-matched 
healthy controls [71-73]. Moreover, the severity of bone loss is 
correlated to the severity of GH deficiency [74]. Accordingly, 
the fracture risk in GH deficiency patients is 2- to 5-fold higher 
than in healthy controls [75,76]. Significant improvements in 
bone mineral density in response to GH treatment were reported 
among males and patients with severe bone loss [77]. Even in 
patients without a history of osteoporosis, GH treatment pre-
vented fractures [78].
4.2. GH treatment lowers the risk of cardiovascular disease 
in patients with GH deficiency, but there is insufficient 
evidence regarding its effects on mortality reduction.
Previous studies have shown that GH deficiency increases the 
risk of cardiovascular disease via its negative effects on meta-
bolic parameters, such as abdominal obesity, insulin resistance, 
and deterioration of lipid panels, and increases in various in-
flammatory markers [79]. GH deficiency has also been reported 
to negatively influence heart function and atherosclerosis by 
causing reduced thickness of the left ventricle, impairment of 
ejection fraction, and diastolic filling in the left ventricle [80]. A 
previous study reported that the cardiovascular mortality rate 
was twice as high in adult patients with GH deficiency than in 
their counterparts without GH deficiency [81]. Svensson et al. 
[82] reported that in patients with hypopituitarism, GH replace-
ment led to lower rates of fatal myocardial infarction and a low-
er mortality rate [83]. A meta-analysis also found that GH re-
placement reduced the mortality rate among male patients with 
hypopituitarism [84], and a domestic study reported a reduction 
in markers of inflammation through GH replacement [70]. GH 
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replacement can be expected to have a positive effect on cardio-
vascular disease. However, the mortality improvement is lower 
for women than for men [80], and the question of whether GH 
replacement can fully restore the long-term negative effects of 
GH deficiency on cardiovascular risk factors remains [83]. 
Therefore, it is still difficult to draw a definite conclusion on 
GH replacement and improvements in cardiovascular mortality, 
and additional longitudinal, large-scale research is required [85].
4.3. GH treatment improves quality of life in patients 
with GH deficiency.
Patients with GH deficiency may experience an impaired 
quality of life due to the deterioration in metabolic parameters 
and physical capacity, as well as because of their increased car-
diovascular risk. Studies measuring the quality of life among 
adult patients diagnosed with GH deficiency using various tools 
in comparison to that of healthy adults found significantly poor-
er results for sleep, social integration, and physical activity 
among patients with GH deficiency, and their physical health 
negatively influenced their occupational status and daily life 
[86]. It was found by Svensson et al. [82] that GH replacement 
improved quality of life, and a domestic study also reported im-
provements in quality of life through increase of bone mineral 
density, lean body mass, and muscular strength, and decrease of 
body fat among healthy Korean women aged 60 or above after 
6 months of GH replacement [87,88].
5. Risks and side effects of growth hormone treatment
The most common side effects of GH treatment are peripheral 
edema, joint pain, carpal tunnel syndrome, sensory disturbanc-
es, and increased blood glucose levels [33,89]. Side effects are 
more prevalent in elderly or obese patients and those who have 
been overtreated with GH [33]. The side effects of GH treat-
ment can last for 3 or more years [90]. In particular, the possi-
bility that GH replacement may cause malignant conditions to 
worsen should be carefully considered in the management of 
hypopituitarism.
5.1. GH treatment is contraindicated in patients with an 
active malignancy (other than basal cell or squamous 
cell skin cancers).
Theoretically, the increased activity of the IGF-1 axis result-
ing from GH treatment can exacerbate malignant tumors, as GH 
and increased IGF-1 levels are independently associated with 
the development of various malignant tumors [91]. Therefore, 
GH treatment is contraindicated in patients with malignancies. 
This recommendation is based on the theoretical possibility that 
GH treatment could increase the size of existing tumors, but 
there is not yet any concrete support for this proposal from clini-
cal research [92]. Inpatients with GH deficiency, research on the 
risk of GH treatment-related recurrence of malignant tumors or 
secondary tumor formation has mostly been conducted among 
childhood cancer patients who had received GH treatment [93-
95]. Although some studies reported a slight increase in the risk 
of secondary tumor formation among childhood cancer patients 
who had previously received GH treatment [94,95], most stud-
ies found no association between GH treatment and the recur-
rence of malignant tumors or secondary tumor formation [96-
103]. These results indicate that if an intracranial residual be-
nign tumor is stable over a long period, there is no need to pro-
hibit GH treatment. GH treatment can be administered to pa-
tients with a history of malignancy if they have been in remis-
sion for at least 1 year without recurrence [104].
5.2. Changes in blood glucose levels should be observed 
during the course of GH treatment in patients with di-
abetes mellitus, who may require their antidiabetic 
medication to be adjusted.
GH and IGF-1 independently influence insulin resistance and 
insulin secretion by pancreatic β-cells [105]. Both increased and 
decreased GH and IGF-1 levels can cause abnormalities in 
blood glucose levels. The elevated blood glucose levels present 
in patients with acromegaly and the increased insulin resistance 
in patients with GH deficiency are clinically observed. Large-
scale clinical studies have reported GH treatment is related to 
insulin resistance and type 2 diabetes [106]. Insulin sensitivity 
following GH treatment varies since abnormlities in blood glu-
cose levels depend on body composition, age, and genetic char-
acteristics. According to a randomized controlled trial conduct-
ed by Hoffman et al. [27], compared to the placebo group, the 
group that received GH treatment had a statistically significant 
13% increase in prediabetes and a 4% increase in diabetes. 
Therefore, when GH treatment is given, careful follow-up on 
diabetes is necessary, and adjustments to anti-diabetic medica-
tion should be considered.
5.3. Thyroid and adrenal gland function should be mon-
itored during GH treatment in patients with hypopitu-
itarism.
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It is common for patients with GH deficiency to have other 
manifestations of hypopituitarism, and thyroid and adrenal 
gland function—even if they are initially normal—should be 
monitored during GH treatment [58]. Hypothyroidism is ac-
companied by reduced secretion of IGF-1 and GH [107,108]. 
Therefore, in order to evaluate GH function accurately, central 
hypothyroidism should be treated first. During treatment, thy-
roid function must be evaluated, since GH treatment can reduce 
free thyroxine levels. Among patients with GH deficiency, 36% 
to 47% of those with normal thyroid function became hypothy-
roid and 16% to 18% of those with hypothyroidism required an 
increase in levothyroxine dose within 3 to 6 months of GH 
treatment [109,110]. When GH treatment is started or the dose 
is changed, central hypothyroidism should be checked after 6 
weeks [111].
In addition, hypothalamic-pituitary-adrenal function should 
be evaluated before and after GH treatment. Since GH sup-
presses the enzyme 11 β-hydroxysteroid dehydrogenase type 1 
converting cortisone to cortisol, the ratio of cortisone to cortisol 
is higher in patients with GH deficiency [108,112]. Therefore, 
even if adrenal insufficiency is present, it might not be diag-
nosed if accompanied by GH deficiency. When GH is given to 
such patients, possible adrenal function deterioration should be 
carefully considered [113,114].
CONCLUSIONS
Although it remains controversial whether GH treatment reduc-
es cardiovascular mortality in patients with hypopituitarism, 
GH treatment in patients with GH deficiency has more benefits 
than harm. It is important to accurately diagnose GH deficiency 
through GH stimulation tests before starting GH treatment. The 
GH dose should be individualized to minimize side effects and 
to maximize clinical efficacy. Side effects and clinical response 
should be monitored regularly while patients are treated with 
the maintenance dose.  
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